A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
More specific conditions that are subtypes of Agranulocytosis in the MeSH hierarchy.
122 drugs (92 approved, 30 experimental)
Phase 3 trials (2)
Organization Involved with Phase 2 Indications (2)